S215: GEMSTONE-201: PRE-PLANNED PRIMARY ANALYSIS OF A MULTICENTER, SINGLE-ARM, PHASE 2 STUDY OF SUGEMALIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY EXTRANODAL NATURAL KILLER/T CELL LYMPHOMA (R/R ENKTL)

• H. Huang,
• R. Tao,
• Y. Yang,
• H. Cen,
• H. Zhou,
• Y. Guo,
• L Zou,
• J. Cao,
• Y. Huang,
• J. Jin,
• L. Zhang,
• H. Yang,
• X. Xing,
• H. Zhang,
• Y. Liu,
• K. Ding,
• X. Zhu,
• T. Fang,
• H. Dai,
• Q. Qi,
• J. Yang

Affiliations

H. Huang

1 Sun Yat-sen University Cancer Center, Guangzhou

R. Tao

2 Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

Y. Yang

3 Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, fuzhou

H. Cen

4 Guangxi Cancer Hospital and of Guangxi Medical University Affiliated Cancer Hospital, nanning

H. Zhou

5 Hunan Cancer Hospital, changsha

Y. Guo

6 Shanghai East Hospital, Tongji University School of Medicine, Shanghai

L Zou

7 State Key Laboratory, Cancer Center, West China Hospital of Sichuan University, chengdu

J. Cao

8 Fudan University Shanghai Cancer Center, Shanghai

Y. Huang

9 The Affiliated Cancer Hospital of Guiyang Medical University, guiyang

J. Jin

10 First Affiliated Hospital, College of Medicine, Zhejiang University, hangzhou

L. Zhang

11 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, wuhan

H. Yang

12 Zhejiang Cancer Hospital, hangzhou

X. Xing

13 Liaoning Cancer Hospital & Institute, Shenyang

H. Zhang

14 Tianjin Medical University Cancer Institute & Hospital, tianjin

Y. Liu

15 Henan Provincial Cancer Hospital, zhengzhou

K. Ding

16 Anhui Provincial Cancer Hospital, Hefei

X. Zhu

17 CStone Pharmaceuticals (Su Zhou) Co., Ltd., Shanghai, China

T. Fang

17 CStone Pharmaceuticals (Su Zhou) Co., Ltd., Shanghai, China

H. Dai

17 CStone Pharmaceuticals (Su Zhou) Co., Ltd., Shanghai, China

Q. Qi

17 CStone Pharmaceuticals (Su Zhou) Co., Ltd., Shanghai, China

J. Yang

17 CStone Pharmaceuticals (Su Zhou) Co., Ltd., Shanghai, China